Pivot et al. conducted a study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for HER2–positive early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.